European Blood Pressure Intensive Control After Stroke

Ischemic Stroke Clinical Trial

— EPICS-Pilot  

Official title:

European Blood Pressure Intensive Control After Stroke - Pilot Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04647292
• Other study ID #: 7580
• Status: Recruiting
• Phase: Phase 2
• Start date: May 2, 2024
• Est. completion date: March 2026

Study information

• Verified date: May 2024
• Source: University College Dublin
• Contact: Katrina Tobin
• Phone: +353 1 716 4576
• Email: katrina.tobin[@]ucd.ie
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack, and current guidelines recommend treatment to a target of <130mmHg for secondary prevention.

Home blood pressure measurement and telemonitoring are acceptable to patients, but there is uncertainty over the use of out of office blood pressure measurements in stroke patients in guidelines.

This is a study designed to establish the feasibility of a larger clinical trial, comparing home blood pressure monitoring, telemonitoring and medication titration with standard care. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.

Description:

Background:

Stroke is the third leading cause of global death, the leading cause of acquired disability and contributes substantially to dementia, cognitive decline, and healthcare costs. Global epidemiological studies such as INTERSTROKE and the Global Burden of Disease study estimated that hypertension is the leading modifiable risk factor for stroke, with a population attributable risk of approximately 50%. Recurrent vascular events (stroke, coronary events, vascular death) cause significant morbidity in ischaemic stroke survivors, affecting approximately 30% at 5 years.

High rates of failure to achieve guideline BP targets (<130mmHg) are reported in clinical practice for patients following ischaemic stroke or TIA. Home blood pressure measurement and telemonitoring is recognised as acceptable to patients from previous studies, and some trials have noted a significant reduction in BP at 12 months. The latest ESO guidelines note continued uncertainty over the use of out-of-office blood pressure measurements for adult patients with ischaemic stroke or TIA due to insufficient data.

This trial will recruit patients with recent stroke/TIA events with systolic BP ≥140 mmHg and randomise them to standard of care or home BP monitoring with telemonitoring and medication titration. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.

Aim:

The aim is to conduct an initial pilot randomised trial in Ireland and European centres involved in the European Stroke Organisation Trials Alliance. This feasibility study will assess key design aspects and establish trial governance, data management, and procedures in preparation for a larger definitive trial.

Methods:

Design: Prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot/feasibility clinical trial, comparing BP patient self-measurement and telemonitoring with office-based monitoring (standard of care) for improved BP control after ischaemic stroke/TIA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 142
• Est. completion date: March 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Age =40

2. Ischaemic stroke1, high-risk TIA, proven by imaging (brain CT/MRI)

3. Living at home and independent (walking without the aid of another person, but may have some help for daily activities)

4. SBP=140mmHg at entry (average of 2 measures, seated, in the same arm, after resting alone in office for 10 minutes)

5. Qualifying event between 30 days and 1 year of randomisation

6. Glomerular filtration rate (eGFR) greater than or equal to 50ml/min/m2 (within 3 months of randomisation)

7. Medically-stable and capable of participating in a randomised trial, including home BP measures, in the opinion of the study physician

8. Willing to provide informed consent (no surrogate consent will apply)

Exclusion Criteria:

1. SBP <110mmHg after 3 minutes of standing or other contra-indication to intensive SBP lowering in opinion of treating clinician (eg. Orthostatic symptoms, syncope or pre syncope, recurrent falls)

2. Qualifying stroke due to intracerebral haemorrhage (ICH), cardio-embolism or other defined causes (eg. dissection, endocarditis, other specified)

3. Severe stenosis or occlusion of large cranio-cervical artery (>70% stenosis/occlusion of cervical carotid, vertebral, or Circle of Willis artery)

4. Unlikely to comply with study procedures due to severe or fatal comorbid illness (eg. dementia, active malignancy, severe frailty) or other factor (eg. inability to travel)

5. Pregnancy or breastfeeding

Related Conditions & MeSH terms

• Ischemia
• Ischemic Attack, Transient
• Ischemic Stroke
• Stroke
• Transient Ischemic Attack

Intervention

Other:
• anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration
A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy. Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly.
• Standard of Care Blood Pressure Management with Antihypertensives
Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP <130mmHg.

Locations

Country	Name	City	State
Ireland	Mater Misericordiae University Hospital	Dublin

Sponsors (15)

Lead Sponsor

Collaborator

University College Dublin

Attikon Hospital, Cork University Hospital, Hospital Universitario La Paz, HRB Stroke Trials Network Ireland, Mater Misericordiae University Hospital, National University of Ireland, Galway, Ireland, Newcastle University, St Vincent's University Hospital, Ireland, Tallaght University Hospital, Universitaire Ziekenhuizen KU Leuven, University Hospital Waterford, University of Calgary, University of Limerick, University of Oslo

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of patients who do not complete the study due to tolerability or other issues	Patients who are not retained in the study will give an insight into anticipated retention in the Phase 3 trial and sample size considerations.	12 months (or end of trial visit)
Other	Ability of sites to rapidly identify eligible patients from clinics and stroke units	The inclusion of prevalent cases already attending stroke clinics or discharged from stroke units within the last year is an important design feature, aimed to rapidly accrue patients into the trial and thus to maximise the duration of follow-up within the terms allowed by funders. This outcome will be judged on the basis of qualitative feedback from participating sites.	12 months (or end of trial visit)
Other	Feasibility of home blood pressure (BP) measures and telemonitoring	This outcome will be judged on the basis of qualitative feedback from participants and the the proportions of participants adhering to the use of home blood pressure diaries.	12 months (or end of trial visit)
Other	Compliance with telemonitoring and feasibility of remote (phone) visits	The feasibility of remote (phone) visits will be assessed by the proportion of patients adhering to participation in remote visit consultations	12 months (or end of trial visit)
Other	Feasibility of remote BP titration	The feasibility of titration of BP based on prescriptions to pharmacies in response to BP telemonitoring	12 months (or end of trial visit)
Other	Barriers to participation of women	Qualitative review to improve the design of a future Phase 3 trial with the aim of reducing barriers to women	12 months (or end of trial visit)
Primary	Difference in mean SBP	The difference in mean SBP between both groups, at 12 months (or last trial visit)	12 months (or last trial visit)
Secondary	Proportions of patients assigned to each arm successfully reaching guideline-based target (SBP<130mmHg) at end of trial visit		12 months (or last trial visit)
Secondary	Time in guideline-based target range	Proportion of SBP measures <130 during trial participation	12 months (or last trial visit)
Secondary	Time taken to reach target	Time taken to reach target SBP<130mmHg	12 months (or last trial visit)
Secondary	Difference in mean diastolic blood pressure (DBP) between groups		12 months (or last trial visit)
Secondary	Change in SBP/DBP from baseline to end-of-trial		12 months (or last trial visit)
Secondary	Time to first composite major adverse cardiovascular event (MACE), and to each component of the composite, stratified as fatal, non-fatal and total	MACE defined as all recurrent stroke, myocardial infarction, cardiac arrest	12 months (or last trial visit)
Secondary	All-cause fatality		12 months (or last trial visit)
Secondary	Comparison of disability in each intervention arm assessed by modified Rankin score	Shift analysis and proportion with no, mild, or moderate disability, Rankin score 0-3	12 months (or last trial visit)
Secondary	Number of dose-titrations required		12 months (or last trial visit)
Secondary	Time required per follow up visit		12 months (or last trial visit)
Secondary	Number of patients lost to follow-up		12 months (or end of trial visit)
Secondary	Number of serious adverse events	Difference in proportion of patients with serious adverse events	12 months (or last trial visit)
Secondary	Number of pre-specified adverse events		12 months (or last trial visit)
Secondary	Change in health related quality of life	Change in EQ5D-5L score (5 domains assessed with scores of 1-5 ranking the severity of impairment, with higher scores indicating poorer quality of life) at last follow-up compared with baseline	12 months (or last trial visit)
Secondary	Change in cognition	Change in Montreal cognitive assessment score (range 0-30) at last follow-up compared with baseline score. A lower score indicates greater cognitive impairment.	12 months (or last trial visit)
Secondary	Qualitative patient feedback obtained via workshops and questionnaires		12 months (or last trial visit)